NSNasim Sohrabifar

Nasim Sohrabifar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nasim Sohrabifar has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Trans-Catheter Aortic Valve Replacement (AVR) in Severe Aortic Stenosis: A 3-year Experience in Modarres Hospital (A Tertiary University Hospital, Tehran, Iran)

    by Mohammad Hassan Namazi, Saeed Alipour-Parsa, Mohammad Khani, Vahid Eslami, Morteza Safi, Hossein Vakili, Habibollah Saadat, Ramin Baghaei Tehrani, Manouchehr Hekmat, Ali Dabbagh, et al.

    Background: Aortic stenosis (AS) is a progressive disease with high mortality if untreated; however, many high-risk patients do not receive surgical aortic valve replacement (AVR) due to comorbidities. Transcatheter aortic valve implantation (TAVI) offers a less invasive therapeutic choice. Objectives: This study evaluated the outcomes of TAVI at the Shahid Modarres Educational and Therapeutic Center in Iran. Methods: In this cross-sectional study, 100 consecutive patients (77.82 ± 6.97 years) with severe symptomatic AS underwent TAVI using balloon-expandable valves under conscious sedation over 3 years. Pre-procedural assessments included echocardiography and computed tomography (CT) angiography. The procedure was performed via transfemoral access under fluoroscopic guidance. Outcomes assessed included procedural complications, mortality at 30 days and 6 months, and echocardiographic data pre- and post-procedure. Results: The TAVI was successful in 99% of patients. Procedural complications occurred in 12%, with a mortality rate of 1%. Post-procedure, the mean pressure gradient (MPG) was 9.75 ± 6.19 mmHg and the peak pressure gradient (PPG) was 19.25 ± 10.15 mmHg. Mortality at 30 days was 3%, increasing to 6% by 6 months, while 23% were hospitalized for any cause within 6 months. Notable correlations were found between gradient improvement (ΔMPG and ΔPPG) and factors such as aortic valve area (AVA) and left ventricular ejection fraction (LVEF). Conclusions: Initial experiences with TAVI at our center indicate it is a safe and effective treatment for high-risk patients with severe AS, with positive mid-term outcomes underscoring the need for careful patient selection and management.

  • Evaluation of circulating levels of miR-135a and miR-193 in patients with sepsis

    by Nazila Behroozizad, Ata Mahmoodpoor, Kamran Shadvar, Roghayeh Asghari Ardebil, Aynour Jalali Pahnvar, Nasim Sohrabifar, Somayeh Kazeminasab

    Background Sepsis is a life-threatening condition where early diagnosis and prognostic awareness provide guidance for selecting the appropriate treatment strategies. A wide variety of biomarker-based studies in clinical medicine provide new insights into personalized medicine for sepsis patients. MiRNAs are endogenous non-coding RNA molecules that have been acting as great potential diagnostic, prognostic and therapeutic biomarkers in various diseases. Methods and results In the present study, the expression levels of two selected miRNAs, including miR-135a and miR-193, were evaluated for their prognostic potential in patients with sepsis. The circulating levels of miRNAs were quantified by quantitative PCR (qPCR) in patients with sepsis (n = 100) and age- and sex-matched healthy controls (n = 100). Statistical findings confirmed the valuable prognostic potential of miR-135a in patients with sepsis, while no significant difference was found between the miR-193 expression level in the patients with sepsis and the controls. Conclusions Circulating levels of miRNA-135a can serve a the prognostic biomarker for patients with sepsis. These findings highlight the importance of miRNAs as signatures in the personalized managements of sepsis.


  • Prognostic potential of circulating cell free mitochondrial DNA levels in COVID-19 patients

    by Ata Mahmoodpoor, Mojtaba Mohammadzadeh, Rogayyeh Asghari, Majid Tagizadeh, Afshin Iranpour, Mansour Rezayi, Aynour Jalali Pahnvar, Babak Emamalizadeh, Nasim Sohrabifar, Somayeh Kazeminasab

    Background In viral infections, mitochondria act as one of the main hubs of the pathogenesis. Recent findings present new insights into the potential role of circulating cell-free mitochondrial DNA (ccf-mtDNA) in COVID-19 pathogenesis by the induction of immune response and aggressive cytokine storm in SARS-CoV-2 infection. Methods and results The levels of ccf-mtDNA were investigated in 102 hospitalized patients with COVID-19 using the quantitative PCR (q-PCR) method. Statistical analysis confirmed a strong association between the levels of ccf-mtDNA and and mortality, ICU admission, and intubation. Also, our findings highlighted the pivotal role of comorbidities as a risk factor for COVID-19 mortality and severity. Conclusion Higher levels of ccf-mtDNA can serve as a potential early indicator for progress and poor prognosis of COVID-19.


  • Open Access

    Is the Cell-Free Circulating Mitochondrial DNA a Potential Biomarker for Atrial Fibrillation?

    by Mohammad Rahmanian, Isa Khaheshi, Mohammad Khani, Reza Bayati, Mohammadamin Ataee, Nasim Sohrabifar

    : Atrial fibrillation (AF), considered the most common tachyarrhythmia, is associated with severe complications, such as ischemic stroke and heart failure. Mitochondria are organelles that supply cells energy by converting various forms of molecules into adenosine triphosphate. Mitochondria has a double-stranded, independent DNA (mtDNA), the copy number of which in peripheral blood is associated with the oxidative stress status in the patient. Oxidative stress is also regarded as a potential factor contributing to AF. This study reviews the association between the cell-free circulating mitochondrial DNA (Cfc-mtDNA) in peripheral blood and AF. We searched for studies on AF and mtDNA; four investigations were included. The three of these studies revealed that the level of Cfc-mtDNA in serum appears to be associated with AF, but there are no similar results about Cfc-mtDNA and Per-AF. In addition, the age and gender of patients do not affect Cfc-mtDNA levels. However, further research is necessary in the future.

  • Investigating the expression level of miR-17-3p, miR-101-3p, miR-335-3p, and miR-296-3p in the peripheral blood of patients with acute myocardial infarction

    by Alireza Bakhshi, Mohammad Khani, Saeed Alipour Parsa, Isa Khaheshi, Mohammad Hassan Namazi, Arash Mazouri, Peyman Bidram, Morteza Safi, Hossein Vakili, Vahid Eslami, et al.

    The role of inflammation has been proven in acute myocardial infarction (AMI) pathogenesis. Due to the effect of NLRP3 gene expression in the inflammation process of MI, we aimed to explore the expression changes and diagnostic power of four inflammation-related miRNAs including miR-17-3p, miR-101-3p, miR-335-3p, miR-296-3p and their potential target, NLRP3, in ST-segment elevation myocardial infarction (STEMI), and non-STEMI (NSTEMI) patients as two major classes of AMI. The expression level of these genes were evaluated in 300 participants equally divided into three groups of STEMI, NSTEMI, and control using quantitative real-time PCR. The expression level of NLRP3 was upregulated in STEMI and NSTEMI patients compared to control subjects. Besides, the expression levels of miR-17-3p, miR-101-3p, and miR-296-3p were significantly downregulated in STEMI and NSTEMI patients compared to controls. The increased expression of NLRP3 had a very strong inverse correlation with miR-17-3p in patients with STEMI and with miR-101-3p in the STEMI and NSTEMI patients. ROC curve analysis showed that the expression level of miR-17-3p had the highest diagnostic power for discrimination between STEMI patients and controls. Remarkably, the combination of all markers resulted in a higher AUC. In summary, there is a significant association between the expression levels of miR-17-3p, miR-101-3p, miR-335-3p, miR-296-3p, and NLRP3 and the incidence of AMI. Although the miR-17-3p expression level has the highest diagnostic power to distinguish between STEMI patients and control subjects, the combination of these miRNAs and NLRP3 could serve as a novel potential diagnostic biomarker of STEMI.


  • Roles of mitochondrial DNA in dynamics of the immune response to COVID-19

    by Ata Mahmoodpoor, Sarvin Sanaie, Zoherh Ostadi, Maqsoud Eskandari, Nazila Behrouzi, Roqayyeh Asghari, Ahmad Zahirnia, Nasim Sohrabifar, Somayeh Kazeminasab


  • Reverse expression pattern of sirtuin-1 and histone deacetylase-9 in coronary artery disease

    by Laleh Heidari, Sayyed Mohammad Hossein Ghaderian, Milad Bastami, Shadi Hosseini, Saeed Alipour Parsa, Sahel Heidari, Hossein Jafari, Nasim Sohrabifar, Maryam Pirhoushiaran

    SIRT1 and HDAC 9 genes are related to inflammation and may contribute to the pathogenesis of coronary artery disease (CAD). We aimed to evaluate the expression level, methylation profile and polymo...


  • Variation in the expression level of MALAT1, MIAT and XIST lncRNAs in coronary artery disease patients with and without type 2 diabetes mellitus

    by Nasim Sohrabifar, Sayyed Mohammad Hossein Ghaderian, Saeed Alipour Parsa, Hamid Ghaedi, Hossein Jafari

    Background: The MALAT1, MIAT, and XIST long noncoding RNAs (lncRNAs) participate in the pathogenesis of complex diseases and also serve as diagnostic markers. The study aimed to assess their expressions in CAD patients with or without T2DM against diabetic and non-diabetic controls. Methods: The expression levels of three lncRNAs in 50 CAD patients (with or without diabetes) and 50 non-CAD subjects (with or without diabetes) were evaluated by using the TaqMan Assay method. Results: MALAT1 and MIAT were upregulated in CAD patients (p Value= .0008 and .0078, respectively). The expression level of XIST was significantly elevated diabetic compared to non-diabetic CAD patients (p Value= .0003). MALAT1 gene had the highest diagnostic power for discrimination of CAD patients from controls (AUC= 0.682, p Value=.001). Conclusions: The current study supports the participation of lncRNAs in the pathogenesis of CAD and T2DM and highlights their potential as diagnostic biomarkers.


  • MicroRNA-copy number variations in coronary artery disease patients with or without type 2 diabetes mellitus

    by Nasim Sohrabifar, Sayyed Mohammad Hossein Ghaderian, Hosein Vakili, Hamid Ghaedi, Borzu Rouhani, Hossein Jafari, Laleh Heidari

    Background: An important cause of Coronary Artery Disease (CAD) is Type 2 Diabetes Mellitus (T2DM). The aim of this study was the evaluation of copy number variations (CNVs) of hsa-miR-93, hsa-miR-122, hsa-miR-192 in CAD patients with or without T2DM. Methods: CNVs of three micro-RNAs in 50 CAD patients and 50 non-CAD subjects both with and without diabetes were evaluated by real-time PCR and compared in three comparison groups namely 1, 2 and 3 (including comparison between CAD and non-CAD, diabetic CAD and non-diabetic CAD and between diabetic CAD and diabetic non-CAD subjects, respectively). Results: There were significant differences in CNVs of hsa-miR-93 between cases and controls in comparison groups 1 and 3 (p = .0310 and .0232, respectively), for hsa-miR-122 in all comparison groups, and for hsa-miR-192 in comparison group 3 (p = .0181). Conclusion: We showed the association of these microRNA-CNVs with CAD, T2DM or both simultaneously.